Clinical Manual for Diagnosis, Prevention and Treatment of Cardiovascular Complications of Cancer Therapy. Part I

Clinical Manual for Diagnosis, Prevention and Treatment of Cardiovascular Complications of Cancer Therapy. Part I

Advances in treatment have led to improved survival of patients with cancer but have also resulted in untoward side effects associated with treatment. Cardiovascular diseases are one of the most frequent of these side effects. Myocardial dysfunction and heart failure, myocardial ischaemia, arrhythmi...

Full description

Bibliographic Details
Main Authors:	I Ye Chazova, S A Tyulyandin, M V Vitsenia, A G Ovchinnikov, M G Poltavskaya, M Yu Gilyarov, T V Martynyuk, E P Panchenko, Yu A Fedotkina, M B Stenina, O P Trophimova, F T Ageev
Format:	Article
Language:	Russian
Published:	IP Morozov P.V. 2017-12-01
Series:	Системные гипертензии
Subjects:	cardiotoxicity chemotherapy anthracyclines trastuzumab left ventricular dysfunction heart failure diagnosis prevention treatment
Online Access:	https://syst-hypertension.ru/2075-082X/article/viewFile/29580/pdf

Similar Items

Clinical Manual for Diagnosis, Prevention and Treatment of Cardiovascular Complications of Cancer Therapy. Part I
by: Chazova I.Ye., et al.
Published: (2017-09-01)

Left Ventricular Regional Wall Motion Abnormality is a Strong Predictor of Cardiotoxicity in Breast Cancer Patients Undergoing Chemotherapy
by: Márcio Vinícius Lins de Barros, et al.
Published: (2018-12-01)

Clinical manual for diagnosis, prevention and treatment of cardiovascular complications of cancer therapy. Parts VI-VII
by: I Ye Chazova, et al.
Published: (2018-03-01)

Clinical Manual for Diagnosis, Prevention and Treatment of Cardiovascular Complications of Cancer Therapy. Parts II-V
by: I Ye Chazova, et al.
Published: (2017-12-01)

Association of Genetic Variants at TRPC6 With Chemotherapy-Related Heart Failure
by: Nadine Norton, et al.
Published: (2020-08-01)

Cardioprotection From Cardiotoxicity
by: Guilherme H. Oliveira, MD, MBA
Published: (2019-09-01)

Cardiovascular toxicities from systemic breast cancer therapy
by: Shuang eGuo, et al.
Published: (2014-12-01)

Cardio-Оncology – New Challenge in Clinical Practice
by: Sladjana Popović, Srdjan Popović, Nikolina Dukić, Jelena Vladičić-Mašić, Olivera Čančar
Published: (2020-06-01)

Cardiotoxicity after Additional Administration of Pertuzumab following Long-Term Trastuzumab: Report of 2 Cases
by: Mayuko Ito, et al.
Published: (2021-02-01)

Strategies to Prevent Cardiovascular Toxicity in Breast Cancer: Is It Ready for Primetime?
by: Robin Kikuchi, et al.
Published: (2020-03-01)

Anthracycline cardiomyopathy
by: Vasiliy Nefedovich Anokhin, et al.
Published: (2011-10-01)

POSSIBILITIES OF IVABRADINE, A SELECTIVE INHIBITOR OF ION F-CHANNELS OF SINUS NODE, IN PREVENTION OF ANTHRACYCLINE CARDIOTOXICITY IN PATIENTS WITH BREAST CANCER
by: Yu. V. Vasyuk, et al.
Published: (2017-05-01)

Clinical manual for diagnosis, prevention and treatment of cardiovascular complications of cancer therapy. Parts VI–VII
by: Chazova I.Ye., et al.
Published: (2018-02-01)

Implications du stress oxydant et du fer dans la cardiotoxicité des anthracyclines et du trastuzumab
by: Guenancia, Charles
Published: (2015)

CARDIOVASCULAR COMPLICATIONS CAUSED BY CHEMOTHERAPY AND TARGETED AGENTS
by: L. V. Bolotina, et al.
Published: (2016-01-01)

The cardiovascular system in patients with anthracycline cardiomiopathy
by: Alexandr T. Teplyakov, et al.
Published: (2017-10-01)

Dexrazoxane in anthracycline cardiotoxicity
by: Abhijit S Nair
Published: (2017-01-01)

Does anthracycline-based chemotherapy in pregnant women with cancer offer safe cardiac and neurodevelopmental outcomes for the developing fetus?
by: Marialuisa Framarino-dei-Malatesta, et al.
Published: (2017-11-01)

Significance of Echocardiography in the Assessment of Left Ventricular Function in Patients Receiving Combined Adjuvant Treatment with Anthracyclines and Trastuzumab / Značaj ehokardiografije u proceni funkcije leve komore kod bolesnica na adjuvantnoj terapji (kombinovana terapija antraciklinima i trastuzumabom)
by: Krstić Ivana, et al.
Published: (2015-09-01)

Analysis of Models of Doxorubicin-Induced Cardiomyopathy in Rats and Mice. A Modern View From the Perspective of the Pathophysiologist and the Clinician
by: Ekaterina Yu Podyacheva, et al.
Published: (2021-06-01)

Efficacy of Physical Exercise to Offset Anthracycline‐Induced Cardiotoxicity: A Systematic Review and Meta‐Analysis of Clinical and Preclinical Studies
by: Willeke R. Naaktgeboren, et al.
Published: (2021-09-01)

Doxorubicin-Induced Cardiotoxicity in Collaborative Cross (CC) Mice Recapitulates Individual Cardiotoxicity in Humans
by: Caroline J. Zeiss, et al.
Published: (2019-08-01)

Assessment of anthracycline-induced long-term cardiotoxicity in patients with hematological malignancies
by: Aws Sabah Al-Rubaye, et al.
Published: (2019-01-01)

Echocardiographic Changes after Treatment with Anthracyclines in Children
by: Hamid Amoozgar, et al.
Published: (2012-03-01)

Механізм розвитку кардіотоксичності за умов використання антрациклінових антибіотиків та аналіз механізмів кардіопротекторної дії лікарських засобів та сполук різних хімічних груп
by: Ірина Володимирівна Ніженковська, et al.
Published: (2016-04-01)

The diagnosis of anthracycline-induced cardiac damage and heart failure
by: Jarosław Dudka, et al.
Published: (2009-05-01)

An Exploration of Heart Failure Risk in Breast Cancer Patients Receiving Anthracyclines with or without Trastuzumab in Thailand: A Retrospective Study
by: Jukapun Yoodee, et al.
Published: (2021-08-01)

Cardio-Oncology: Learning From the Old, Applying to the New
by: Jun-ichi Abe, et al.
Published: (2020-11-01)

Clinical Manual for Diagnosis, Prevention and Treatment of Cardiovascular Complications of Cancer Therapy. Parts II–V
by: Chazova I.Ye., et al.
Published: (2017-11-01)

Physical activity during and after breast cancer therapy and associations of baseline physical activity with changes in cardiac function by echocardiography
by: Jenica N. Upshaw, et al.
Published: (2020-09-01)

Electrocardiographic characteristics of Nigerian children on anthracycline-based chemotherapy: A preliminary report
by: I D Peter, et al.
Published: (2017-01-01)

Natural Products Counteracting Cardiotoxicity during Cancer Chemotherapy: The Special Case of Doxorubicin, a Comprehensive Review
by: Izabela Koss-Mikołajczyk, et al.
Published: (2021-09-01)

Efficacy and safety of carvedilol in combination with bronchodilators in patients with CHF of ischemic origin and COPD.
by: Vladimir V. Evdokimov, et al.
Published: (2019-04-01)

Early Detection and Monitoring of Cancer Chemotherapy-Related Left Ventricular Dysfunction by Imaging Methods
by: Mario Luiz Ribeiro, et al.
Published: (2019-02-01)

Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series
by: Sarju Ganatra, et al.
Published: (2019-01-01)

Systemic and cardiac susceptibility of immune compromised mice to doxorubicin
by: Amanda J. Favreau-Lessard, et al.
Published: (2019-04-01)

Skip Soft Definitions and Focus on Hard Endpoints∗
by: Juan C. Lopez-Mattei, MD, et al.
Published: (2019-12-01)

Cardio-oncology: need for novel structures
by: Lars Michel, et al.
Published: (2019-01-01)

Pregnancy and Cardiomyopathy After Anthracyclines in Childhood
by: Kara Annette Thompson
Published: (2018-03-01)

The effect of anthracyclines in minimal doses on cardiac function of children under chemotherapy
by: Shiva Rahimi Dehgolan, et al.
Published: (2014-07-01)

Cannot write session to /tmp/vufind_sessions/sess_juafq4m2sc5u0im86gvqsg8ll7